(MedPage Today) — A study presented at the American Society of Clinical Oncology (ASCO) annual meeting suggested that circulating tumor (ct)DNA-based measurable residual disease (MRD) assessment may provide prognostic information for patients…
Source: MedPage Today — Headlines
